<DOC>
	<DOCNO>NCT01824394</DOCNO>
	<brief_summary>To demonstrate safety effectiveness nMARQ Catheter System [ nMARQ ] compare THERMOCOOL® Navigational Family catheter treat subject drug-refractory symptomatic paroxysmal atrial fibrillation ( PAF ) .</brief_summary>
	<brief_title>nMARQ™ Pulmonary Vein Isolation System Treatment Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . Patients symptomatic paroxysmal AF least one AF episode document within one ( 1 ) year prior enrollment . Documentation may include ECG , transtelephonic monitor ( TTM ) , Holter monitor ( HM ) , telemetry strip . 2 . Patients fail least one antiarrhythmic drug ( AAD ; class I III , atrioventricular ( AV ) nodal block agent beta blocker calcium channel blocker ) evidence recurrent symptomatic AF , intolerance AAD . 3 . Preprocedure anticoagulation warfarin , rivaroxaban , apixaban . 4 . Age 18 year old . 5 . Signed Patient Informed Consent Form ( ICF ) . 6 . Able willing comply pre , post , followup testing requirement . 1 . AF secondary electrolyte imbalance , thyroid disease , reversible noncardiac cause . 2 . Previous ablation atrial fibrillation . 3 . Patients amiodarone time past 3 month prior enrollment . 4 . AF episodes lasting &gt; 7 day . 5 . Any cardiac surgery within past 60 day ( 2 month ) . 6 . Any valvular cardiac surgical procedure ( i.e. , ventriculotomy , atriotomy , valve repair replacement presence prosthetic valve ) . 7 . Coronary artery bypass graft ( CABG ) procedure within last 180 day ( 6 month ) . 8 . Awaiting cardiac transplantation cardiac surgery within next 365 day ( 12 month ) . 9 . Documented leave atrial thrombus imaging . 10 . History document thromboembolic event within past one ( 1 ) year . 11 . Diagnosed atrial myxoma . 12 . Presence implant cardioverter defibrillator ( ICD ) . 13 . Significant pulmonary disease , ( e.g. , restrictive pulmonary disease , constrictive chronic obstructive pulmonary disease ) disease malfunction lungs respiratory system produce chronic symptom . 14 . Significant congenital anomaly medical problem opinion investigator would preclude enrollment study . 15 . Women pregnant ( evidenced pregnancy test subject childbearing age potential ) breast feeding . 16 . Acute illness active systemic infection sepsis . 17 . Unstable angina . 18 . Myocardial infarction within previous 60 day ( 2 month ) . 19 . Left ventricular ejection fraction &lt; 40 % . 20 . History blood clot bleed abnormality . 21 . Contraindication anticoagulation ( i.e. , heparin , dabigatran , Vitamin K Antagonists warfarin ) . 22 . Life expectancy le 365 day ( 12 month ) . 23 . Enrollment investigational study evaluate another device drug . 24 . Uncontrolled heart failure NYHA Class III IV heart failure . 25 . Presence intramural thrombus , tumor abnormality precludes catheter introduction manipulation . 26 . Presence condition precludes vascular access . 27 . Left atrial size &gt; 50 mm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>nMARQ</keyword>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Drug Refractory</keyword>
	<keyword>Radio Frequency</keyword>
</DOC>